FluoGuide A/S issues warrants to Board members, management and employees
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Copenhagen, Denmark, 31 July 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that based on the approved Incentive program from 9 February 2021, FluoGuide is issuing 128,175 warrants to certain members of the Board of Directors, management, and employees.
Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 45,000 warrants to certain members of the Board of Directors and by issuing 83,175 warrants to employees and management. All warrants are issued free of change.
Warrants are issued to ensure alignment of interests between the Company’s employees, management, and shareholders. The Company believes that the issue of warrants will strengthen the achievement of FluoGuide’s short-term and long-term goals to support the Company’s business strategy, sustainability, and value creation for the benefit of shareholders.
The warrants are issued in accordance with FluoGuide’s authorization in Clause 3.1.1 and Clause 3.2.1 of the Articles of Association as adopted by the shareholders acting in general meeting.
Each warrant confers the right to subscribe for (1) one new share in FluoGuide. The exercise price is fixed at SEK 79.00 per share of nominal DKK 0.1. The warrants issued vest with 1/36 per month from 1 July 2023.
The warrants represent a total dilution of 1.1% of the current share capital, if vested and exercised. The warrant program is the third warrant program to FluoGuide employees, management, and Board of Directors. The first warrant program was issued in May 2021 and the second in March 2022.
Vested warrants may be exercised in two annual exercise periods of two weeks following publication of respectively the Annual Report and the Interim half-year report. Warrants that have not been exercised 31 July 2033 at the latest, will lapse automatically. The detailed terms of all warrants issued by the Company can be found in the Articles of Association on the Company’s website under https://fluoguide.com/investor/compliance/, following registration with the Danish Business Authorities.
For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
+45 24 25 62 66
ma@fluoguide.com
Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se
About FluoGuide
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. This improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company has demonstrated efficacy of FG001 as well as it being well tolerated and safe in the completed proof-of-concept clinical study (phase I/IIa) in patients with aggressive brain cancer (high grade glioma) that undergo surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial. In addition, FluoGuide has explored FG001 in lung cancer, as well as in the ongoing phase lla trial in head & neck cancer. Also a trial in meningioma and low grade glioma is commencing.
FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker “FLUO”.
Read more about FluoGuides pipeline, technology and upcoming events on www.fluoguide.com